EGFR and non-small cell lung carcinoma: Our study analyzed treatment outcomes for NSCLC patients in Thailand, particularly real-world clinical benefit of EGFR-TKI therapy for EGFRm-positive NSCLC patients at the time of EGFR-TKI could not reimburse for UC and SSS patients in Thailand.